A seat at the table for people with Parkinson's disease

Morgan, Jules

doi:10.1016/s1474-4422(15)00246-x

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is confounded by a rapidly ageing global population, correlating with an increasing number of sporadic cases of PD. In the United Kingdom alone it is believed that about 0.2% of the population are living with PD, affecting an estimated 127,000 people, and currently costing the NHS approximately £212 million per year [23]. This highlights the importance of discovering new methods to diagnose, treat and especially prevent neurodegeneration associated with PD and related synucleinopathies, and to better understand their pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

Meade

Fairlie

Mason

2019

Mol Neurodegeneration

318

225

View full text Add to dashboard Cite

Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). All diseases are determined by αS aggregate deposition but can be separated into distinct pathological phenotypes and diagnostic criteria. Here we attempt to reinterpret the literature, particularly in terms of how αS structure may relate to pathology. We do so in the context of a rapidly evolving field, taking into account newly revealed structural information on both native and pathogenic forms of the αS protein, including recent solid state NMR and cryoEM fibril structures. We discuss how these new findings impact on current understanding of αS and PD, and where this information may direct the field.

show abstract

Section: Introductionmentioning

confidence: 99%

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

Meade

Fairlie

Mason

2019

Mol Neurodegeneration

318

225

View full text Add to dashboard Cite

show abstract

“…Now, it has been agreed that α-syn misfolding and subsequent aggregation contribute significantly to DA neuron degeneration in PD. This is complicated by a fast-aging global population, which coincides with an increase in the number of sporadic occurrences of PD [ 81 , 82 ].…”

Section: α-Syn Structure Aggregation and Degradationmentioning

confidence: 99%

Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

Wang

et al. 2022

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. The classical behavioral defects of PD patients involve motor symptoms such as bradykinesia, tremor, and rigidity, as well as non-motor symptoms such as anosmia, depression, and cognitive impairment. Pathologically, the progressive loss of dopaminergic (DA) neurons in the substantia nigra (SN) and the accumulation of α-synuclein (α-syn)-composed Lewy bodies (LBs) and Lewy neurites (LNs) are key hallmarks. Glia are more than mere bystanders that simply support neurons, they actively contribute to almost every aspect of neuronal development and function; glial dysregulation has been implicated in a series of neurodegenerative diseases including PD. Importantly, amounting evidence has added glial activation and neuroinflammation as new features of PD onset and progression. Thus, gaining a better understanding of glia, especially neuron-glia crosstalk, will not only provide insight into brain physiology events but also advance our knowledge of PD pathologies. This review addresses the current understanding of α-syn pathogenesis in PD, with a focus on neuron-glia crosstalk. Particularly, the transmission of α-syn between neurons and glia, α-syn-induced glial activation, and feedbacks of glial activation on DA neuron degeneration are thoroughly discussed. In addition, α-syn aggregation, iron deposition, and glial activation in regulating DA neuron ferroptosis in PD are covered. Lastly, we summarize the preclinical and clinical therapies, especially targeting glia, in PD treatments.

show abstract

“…Parkinson's disease (PD) represents a global public health issue, with millions of affected patients worldwide. However, many regions around the world still lack sufficient resources to provide adequate care to PD patients [1,2]. Moreover, a lack of satisfactory knowledge amongst medical specialists may present a barrier for PD patients to access suitable treatments, particularly in developing nations [3,4], where PD knowledge is often insufficient [4].…”

Section: Introductionmentioning

confidence: 99%

Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic

et al. 2020

View full text Add to dashboard Cite

Background: Lao People's Democratic Republic (Lao PDR) has only nine neurologists for seven million people; none have formal training in Parkinson's disease (PD). Medical specialists require sufficient PD knowledge to provide high-quality care. Methods: This study outlines a Centre-to-Centre programme for developing PD expertise in underserved regions through a tailored two-year educational enterprise between an established movement disorder mentor centre at Chulalongkorn University in Thailand and mentee centres in Lao PDR. Background knowledge of 80 Laotian physicians was assessed using a validated PD knowledge questionnaire containing 26 questions divided into 3 sections (diagnosis, therapeutic options, disease course) before and immediately after one-day kick-start training. Responses were compared across physicians' demographic groups. Results: Of 80 respondents, 50 (62.5%) were board-certified physicians, of which 27 (54%) specialised in internal medicine. Apparent knowledge gaps were shown by a 51.2% correct response rate for total score, 52.8% for diagnosis, 50.6% for therapeutic options, and 48.2% for disease course. No significant differences in total score or any domain sub-scores between neurologists and other specialties were found. Many did not know which non-motor symptoms could occur as prodromal symptoms or late in course of PD. Incorrect responses mainly reflected a lack of knowledge of the impact of medication on disease. Total and domain sub-scores significantly improved after the course (p < 0.05, each). The size of difference of the means was

show abstract

A seat at the table for people with Parkinson's disease

Cited by 7 publications

References 0 publications

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic

Contact Info

Product

Resources

About